MEI Pharma and Kyowa Kirin Announce Publication in The Lancet Oncology of Data from Phase 1b Clinical Study of Zandelisib in Patients with Relapsed or Refractory B-cell Malignancy

Stock Information for MEI Pharma Inc.

Loading

Please wait while we load your information from QuoteMedia.